Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
24.5 EUR | -1.45% | -4.22% | -33.77% |
May. 31 | Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment | MT |
May. 31 | Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.77% | 1.77B | |
+47.02% | 57.87B | |
+41.28% | 40.25B | |
-6.92% | 39.94B | |
-5.16% | 28.54B | |
+11.38% | 26.4B | |
-20.53% | 19.33B | |
+29.81% | 12.4B | |
-0.86% | 12.23B | |
+24.44% | 12.2B |
- Stock Market
- Equities
- GLPG Stock
- News Galapagos NV
- RBC Cuts Price Target on Galapagos to $38 From $41, Keeps Sector Perform Rating